← Eichor
Condition: Epidermolysis Bullosa Eb Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Epidermolysis Bullosa Eb

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Phase 3 · 1 location(s) · Paradigm Therapeutics · NCT07482787Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Phase 1/Phase 2 · 1 location(s) · M. Peter Marinkovich · NCT06834035A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
Phase 2 · 4 location(s) · Centre Hospitalier Universitaire de Nice · NCT06509984A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Phase 2 · 9 location(s) · Xinnate AB · NCT06594393Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® P
NA · 5 location(s) · Lohmann & Rauscher · NCT07312513
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.